 Interneuron changed its name to Indevus Pharmaceuticals and Cooper remained as CEO until the company was purchased in 2009 by Endo Pharmaceuticals.While at Indevus, Cooper oversaw the FDA approval and commercial introduction of several drugs for urological and endocrinological conditions.He has served on the boards of directors of multiple public and privately held biotechnology companies.